8-K: Spruce Biosciences' TA-ERT Shows Long-Term Efficacy in MPS IIIB

Spruce Biosciences announced positive long-term data for its tralesinidase alfa enzyme replacement therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB), demonstrating preserved cognitive and motor outcomes.

Summary

• Long-term administration of tralesinidase alfa enzyme replacement therapy (TA-ERT) resulted in rapid and durable reduction of heparan sulfate (CSF HS-NRE) in patients with Sanfilippo Syndrome Type B (MPS IIIB).
• TA-ERT preserved cognitive and non-cognitive outcomes, including communication and motor skills, over a six-year period compared to untreated natural history patients.
• The therapy stabilized cognitive function as assessed by Bayley-III Cognitive Raw Score (BSID-C) and cortical gray matter volume, which declined in untreated patients.
• TA-ERT normalized liver and spleen volume in treated patients.
• The safety profile of TA-ERT was consistent with intracerebroventricular (ICV) administration, with approximately 6,000 doses administered to 22 patients over six years.
• New analysis using the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) showed stabilization in receptive and expressive communication, as well as fine and gross motor skills.
• A case study of two siblings, one treated with TA-ERT and one untreated, showed the treated sibling displayed higher cognitive, language, and motor functioning at a similar age.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as highly positive, given the strong long-term clinical data for TA-ERT in a fatal disease with no approved therapies, indicating significant therapeutic potential and a clear path to regulatory submission.

Positives

• Rapid and durable normalization of cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE), a surrogate endpoint reasonably likely to predict clinical benefit.
• Stabilized cognitive function (Bayley-III Cognitive Raw Score) relative to declines seen in untreated natural history patients.
• Stabilized cortical gray matter volume and normalized liver and spleen volume.
• Stabilization in receptive and expressive communication, as well as both fine and gross motor skills, compared to decline in untreated natural history patients.
• Safety profile consistent with intracerebroventricular administration over ~6,000 doses administered to 22 patients over six years.
• Case study demonstrated clear divergence in cognitive and functional ability between a treated and untreated sibling, highlighting TA-ERT's potential.

Risks

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• Risks and uncertainties associated with the Company's business in general.
• Impact of geopolitical and macroeconomic events.
• Risks described under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequently filed Quarterly Reports on Form 10-Q.

Future Outlook

The Company aims to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data. It plans to advance this program through a biologics license application (BLA) submission and potential U.S. FDA approval. TA-ERT is anticipated to be the first and best-in-class disease-modifying therapy to treat MPS IIIB.

Management Comments

• Nicole Muschol, M.D., Principal Investigator: "This long-term data supports tralesinidase alfa enzyme replacement therapy as potentially the first disease-modifying treatment option for individuals living with Sanfilippo Syndrome Type B, a fatal condition for which no approved therapies currently exist."
• Nicole Muschol, M.D.: "The stabilization and preservation of cognitive function, receptive and expressive communication, and fine and gross motor skills observed over six years of TA-ERT treatment are meaningful and provide hope for the families and patients affected by this devastating disorder."
• Kirk Ways, M.D., Ph.D., Chief Medical Officer of Spruce Biosciences: "This dataset represents an important milestone in the development of TA-ERT and reflects our commitment to generating the rigorous safety and efficacy data needed to deepen our understanding of this potential firstand best-in-class therapy."
• Kirk Ways, M.D., Ph.D.: "Seeing sustained normalization of CSF HS-NRE alongside long-term stabilization of cognitive function, communication, and motor skills strengthens our confidence in the potential of TA-ERT and reinforces our dedication to working closely with the Sanfilippo community to responsibly advance this program through a biologics license application submission and potential U.S. FDA approval."
• Irene Chang, M.D., Associate Professor at the University of California, San Francisco: "When we compare clinical observations at a similar age range between the treated and untreated siblings, we see a clear divergence in cognitive and functional ability, demonstrating the potential of TA-ERT to be a novel and clinically meaningful treatment option for children and families impacted by MPS IIIB."

Industry Context

StockSavvy.ai notes that Sanfilippo Syndrome Type B (MPS IIIB) is an ultra-rare, fatal genetic disease with no currently approved therapies. The positive long-term data for TA-ERT positions Spruce Biosciences as a potential pioneer in addressing a critical unmet medical need, potentially establishing a first-in-class disease-modifying treatment in this orphan disease space.

Comparison to Industry Standards

• The filing compares TA-ERT's efficacy against the natural history of MPS IIIB, where untreated patients experience declines in cognitive function, communication, and motor skills.
• A unique case study compared a treated sibling with an untreated sibling, controlling for genetic, environmental, and socioeconomic variables, demonstrating a clear divergence in cognitive and functional ability in favor of the treated individual.

Stakeholder Impact

• Shareholders: Potential for significant value creation due to promising clinical data for a first-in-class therapy addressing a high unmet medical need.
• Patients and Families: Offers substantial hope for a fatal genetic disease with no current approved treatments, potentially improving quality of life and extending lifespan.
• Regulatory Authorities: Will be involved in reviewing the upcoming Biologics License Application (BLA) submission for TA-ERT.

Next Steps

• Advance the TA-ERT program through a biologics license application (BLA) submission.
• Seek potential U.S. FDA approval for TA-ERT for MPS IIIB.

Key Dates

Recommendation

The long-term clinical data for TA-ERT in MPS IIIB is exceptionally positive, demonstrating significant stabilization of cognitive and motor functions and reduction of disease markers compared to the natural progression of this fatal disease. Given the absence of approved therapies for MPS IIIB, TA-ERT's potential as a first-in-class, disease-modifying treatment represents a substantial market opportunity and addresses a critical unmet medical need. The robust safety profile and the stated intention to pursue a BLA submission and FDA approval make this a highly compelling investment opportunity for a seasoned investor, suggesting strong future growth potential.

Keywords

Sanfilippo Syndrome Type B, MPS IIIB, Tralesinidase Alfa, TA-ERT, Enzyme Replacement Therapy, Neurological Disorders, Clinical Trial Results, Biopharmaceutical, Orphan Disease, Cognitive Function, Motor Skills, Heparan Sulfate